These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 24876103)
21. BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients. Cho HR; Jeon H; Park CK; Park SH; Kang KM; Choi SH Sci Rep; 2017 Dec; 7(1):17740. PubMed ID: 29255149 [TBL] [Abstract][Full Text] [Related]
23. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684 [TBL] [Abstract][Full Text] [Related]
25. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588 [TBL] [Abstract][Full Text] [Related]
26. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263 [TBL] [Abstract][Full Text] [Related]
27. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646 [TBL] [Abstract][Full Text] [Related]
28. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985 [TBL] [Abstract][Full Text] [Related]
29. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332 [TBL] [Abstract][Full Text] [Related]
30. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis. Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868 [TBL] [Abstract][Full Text] [Related]
31. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826 [TBL] [Abstract][Full Text] [Related]
32. In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines. Clément A; Doyen M; Fauvelle F; Hossu G; Chen B; Barberi-Heyob M; Hirtz A; Stupar V; Lamiral Z; Pouget C; Gauchotte G; Karcher G; Beaumont M; Verger A; Lemasson B NMR Biomed; 2021 Jun; 34(6):e4490. PubMed ID: 33599048 [TBL] [Abstract][Full Text] [Related]
37. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas. Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678 [TBL] [Abstract][Full Text] [Related]
38. Friend or foe-IDH1 mutations in glioma 10 years on. Huang LE Carcinogenesis; 2019 Nov; 40(11):1299-1307. PubMed ID: 31504231 [TBL] [Abstract][Full Text] [Related]
39. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044 [TBL] [Abstract][Full Text] [Related]
40. Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics. Weeks J; Strom AI; Widjaja V; Alexander S; Pucher DK; Sohl CD Biomolecules; 2021 May; 11(5):. PubMed ID: 34065652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]